Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
Pharmacokinetics of ofloxacin (OFX) was studied in patients on continuous ambulatory peritoneal dialysis (CAPD) carrying out three exchanges per day. In 11 patients given 300 mg of OFX orally, serum OFX concentration peaked at 2.44 mg/l 3.7 hours after administration and the mean elimination half-life of OFX was 25 hours. OFX concentrations in peritoneal fluid underwent cyclical changes with each change of solutions, reaching beyond 0.5 mg/l after 2 hours of equilibration. There was a highly significant correlation between corresponding serum and peritoneal fluid concentrations of OFX after an 8 h equilibration (r = 0.85, p less than 0.001). In 5 patients given a 400 mg loading dose followed by 200 mg of OFX per day for 7 days, trough serum OFX concentrations ranged from 1.35 to 7.00 mg/l and no adverse effects were noticed. CAPD per exchange removed less than 2% of the total dose of OFX given.
D000328:Adult; D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001202:Ascitic Fluid / Q000032:analysis; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000032:analysis / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010538:Peritonitis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D010078:Oxazines; D015242:Ofloxacin; D003404:Creatinine